RADT-18. NEOADJUVANT (PRE RADIOTHERAPY) TEMOZOLOMIDE FOLLOWED BY RADIATION THERAPY WITH CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME

Abstract BACKGROUD AND PURPOSE To evaluate the effect of neoadjuvant [pre-radiotherapy(RT)] temozolomide (TMZ) in glioblastoma multiforme (GBM) patients in terms of overall survival(OS) and progression free survival (PFS). MATERIAL AND METHODS Patients with diagnosed GBM are treated with neoadjuvant...

Full description

Saved in:
Bibliographic Details
Published inNeuro-oncology (Charlottesville, Va.) Vol. 23; no. Supplement_6; p. vi45
Main Authors Prajapati, Chinmaykumar, Mehta, Maitrik, Kunikullaya, U Suryanarayan
Format Journal Article
LanguageEnglish
Published US Oxford University Press 12.11.2021
Online AccessGet full text

Cover

More Information
Summary:Abstract BACKGROUD AND PURPOSE To evaluate the effect of neoadjuvant [pre-radiotherapy(RT)] temozolomide (TMZ) in glioblastoma multiforme (GBM) patients in terms of overall survival(OS) and progression free survival (PFS). MATERIAL AND METHODS Patients with diagnosed GBM are treated with neoadjuvant( pre RT) TMZ followed by concurrent RT-TMZ and adjuvant TMZ. The Kaplan-Meier method is used to estimate OS the differences between groups. RESULTS Twenty five patients are match with inclusion criteria. Age group, Recurvsive partitioning analysis (RPA) class and extent of surgery are found to effect on overall survival but statistically not significant. At end of study, 40 percent patients are alive with 9 months PFS and 11 months OS. CONCLUSION The neo-adjuvant TMZ with concomitant and adjuvant TMZ is feasible and safe which is associated with an encouraging favorable long-term survival with acceptable toxicity.
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/noab196.176